Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: a 2017 Update

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2017 Jun 17

PMID 28620797

Citations 1002

Authors

Masao Omata

Ann-Lii Cheng

Norihiro Kokudo

Masatoshi Kudo

Jeong Min Lee

Jidong Jia

Ryosuke Tateishi

Kwang-Hyub Han

Yoghesh K Chawla

Shuichiro Shiina

Wasim Jafri

Diana Alcantara Payawal

Takamasa Ohki

Sadahisa Ogasawara

Pei-Jer Chen

Cosmas Rinaldi A Lesmana

Laurentius A Lesmana

Rino A Gani

Shuntaro Obi

A Kadir Dokmeci

Shiv Kumar Sarin

Affiliations

Soon will be listed here.

Abstract

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.

Citing Articles

Association between single nucleotide polymorphisms in PNPLA3, TM6SF2 and MBOAT7 genes and markers of cancer aggressiveness in a Sri Lankan NASH-related HCC cohort.

Samarasinghe S, Hewage A, Siriwardana R, Tennekoon K, Niriella M, De Silva S BMC Gastroenterol. 2025; 25(1):151.

PMID: 40065199 PMC: 11892176. DOI: 10.1186/s12876-025-03738-w.

Automated detection of small hepatocellular carcinoma in cirrhotic livers: applying deep learning to Gd-EOB-DTPA-enhanced MRI.

Lei J, Xu Y, Zhu Y, Jiang S, Tian S, Zhu Y Abdom Radiol (NY). 2025; .

PMID: 40059243 DOI: 10.1007/s00261-025-04853-8.

Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.

Pan X, Zhou Y, Li Z, Guo P, Zeng J, Dong X Commun Med (Lond). 2025; 5(1):65.

PMID: 40050645 PMC: 11885828. DOI: 10.1038/s43856-025-00784-z.

Pilot study of an arterial enhancement fraction-based model for progression prediction in HCC undergoing chemoembolization.

Chai B, Xiang D, Zhou G, Zheng C Front Oncol. 2025; 15:1489450.

PMID: 40046631 PMC: 11879821. DOI: 10.3389/fonc.2025.1489450.

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.

Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C Hepatol Int. 2025; .

PMID: 40016576 DOI: 10.1007/s12072-024-10774-3.

References

Xu P, Yan F, Wang J, Lin J, Ji Y . Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging. 2009; 29(2):341-9. DOI: 10.1002/jmri.21650. View

Yin J, Li N, Han Y, Xue J, Deng Y, Shi J . Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31(29):3647-55. DOI: 10.1200/JCO.2012.48.5896. View

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T . Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS One. 2016; 11(8):e0161303. PMC: 4990272. DOI: 10.1371/journal.pone.0161303. View

Cho L, Yang J, Ko K, Park B, Shin A, Lim M . Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2010; 128(1):176-84. DOI: 10.1002/ijc.25321. View

Yoo H, Lee J, Lee M, Kim S, Lee J, Han J . Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. Invest Radiol. 2008; 43(7):538-46. DOI: 10.1097/RLI.0b013e3181768d96. View

Bruix J, Gores G, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. PMC: 4337888. DOI: 10.1136/gutjnl-2013-306627. View

Kong Y, You H, Jia J . Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense. Hepatol Int. 2016; 10(2):239-41. DOI: 10.1007/s12072-016-9714-9. View

Llovet J, Decaens T, Raoul J, Boucher E, Kudo M, Chang C . Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013; 31(28):3509-16. DOI: 10.1200/JCO.2012.47.3009. View

Ferenci P, Fried M, LaBrecque D, Bruix J, Sherman M, Omata M . World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010; 19(3):311-7. View

10.

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

11.

Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K . Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008; 134(7):1908-16. DOI: 10.1053/j.gastro.2008.02.091. View

12.

Chung J, Park J, Han J, Choi B, Han M, Lee H . Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology. 1996; 198(1):33-40. DOI: 10.1148/radiology.198.1.8539401. View

13.

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

14.

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S . Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011; 54(3):868-78. DOI: 10.1002/hep.24451. View

15.

Lu S, Su W, Yang S, Chang T, Cheng K, Wu J . Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer. 2006; 119(8):1946-52. DOI: 10.1002/ijc.22045. View

16.

Corrao G, Bagnardi V, Zambon A, La Vecchia C . A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004; 38(5):613-9. DOI: 10.1016/j.ypmed.2003.11.027. View

17.

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View

18.

Zidan A, Scheuerlein H, Schule S, Settmacher U, Rauchfuss F . Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012; 12(10 HCC):e6894. PMC: 3517809. DOI: 10.5812/hepatmon.6894. View

19.

Di Stasi M, Buscarini L, Livraghi T, Giorgio A, Salmi A, de Sio I . Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol. 1997; 32(11):1168-73. DOI: 10.3109/00365529709002998. View

20.

Shi J, Zhu L, Liu S, Xie W . A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005; 92(3):607-12. PMC: 2362087. DOI: 10.1038/sj.bjc.6602333. View